Replies to post #7153 on Vericel Corp. (VCEL)

[lasers]

Now that is a very good point that you are making.

Because the trial met the primary endpoint, patients who received placebo or were randomized to ixmyelocel-T in the double-blind portion of the trial but did not receive ixmyelocel-T have been offered the option to receive ixmyelocel-T. We successfully treated the last patients in February 2017 and the last follow-up visit will occur approximately one year later.

More patients would most definitely benefit $VCEL DCM arguments for FDA Commercial approval. If these "placebo" patients were deteriorating and $VCEL's Ixcell-DCM reversed the deterioration , that would most definitely be in $VCEL's favor.